Case Study Mitigating Risk in Biosimilar Development

With an expected $67 billion worth of licenses on organic items lapsing before 2020 and governments forced to diminish quickly rising human services costs, biosimilars speak to a noteworthy open door for the pharmaceutical business. Biosimilars are exceptionally like their authorized reference item not withstanding minor contrasts as excipients in the plan; likewise there are no wonderful contrasts between the biologicals and the reference item as far as wellbeing, immaculateness, and strength. However, until a global development strategy is adopted, regulatory, therapeutic and legal challenges remain.

  •  Impact of FDA Guidance on Substitution Policies
  • Chronicles of a Biosimilar Production Facility 
  • challenges in developing monoclonal biosimilars
  •  Impact of FDA Guidance on Substitution Policies
  • Chronicles of a Biosimilar Production Facility 
  • challenges in developing monoclonal biosimilars

Related Conference of Case Study Mitigating Risk in Biosimilar Development

Case Study Mitigating Risk in Biosimilar Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in